---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-002496"
form_type: "8-K"
ticker: "ARMP"
cik: "0000921114"
company_name: "Armata Pharmaceuticals, Inc."
filed_at: "2023-01-10T23:59:59+00:00"
generated_at: "2026-06-20T17:23:33.454068+00:00"
event_type: "debt"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Armata closes $30M secured convertible credit from Innoviva at 8%, due Jan 2024

## Summary
- Gross proceeds $30M from Innoviva Strategic Opportunities LLC, Armata's largest shareholder, at 8% interest, matures Jan 10, 2024.
- Loan converts to common stock upon qualified financing at 15% discount to investors' price; lender option to convert after SEC registration effective at greater of book value or $1.52/share.
- Proceeds used to fund clinical development of AP-PA02 and AP-SA02 and complete cGMP manufacturing facility.
- Loan secured by substantially all assets of Armata and its domestic/foreign material subsidiaries; no warrants issued.

## SEC filing metadata
- accession: 0001104659-23-002496
- form_type: 8-K
- ticker: ARMP
- cik: 0000921114
- company_name: Armata Pharmaceuticals, Inc.
- filed_at: 2023-01-10T23:59:59+00:00
- event_type: debt
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.03, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/921114/000110465923002496/0001104659-23-002496-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/921114/000110465923002496/tm232848d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-002496
- JSON: https://secwatch.observer/filing/0001104659-23-002496.json
- Plain text: https://secwatch.observer/filing/0001104659-23-002496.txt

## Key facts
- Debt Financings
  Armata Pharmaceuticals, Inc. incurred term loan of $30 million with Innoviva Strategic Opportunities LLC at 8.0% per annum maturing January 10, 2024.
  - Instrument: term loan
  - Principal: $30 million
  - Counterparty: Innoviva Strategic Opportunities LLC
  - Rate: 8.0% per annum
  - Maturity: January 10, 2024
  - Event: incurrence
  source text: The Credit Agreement provides for a secured term loan facility in an aggregate amount of $30 million (the “Loan”) at an interest rate of 8.0% per annum, and has a maturity date of January 10, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/921114/000110465923002496/0001104659-23-002496-index.htm
- Material Agreements
  Armata Pharmaceuticals, Inc. entered into Credit Agreement with Innoviva Strategic Opportunities LLC valued at $30 million (effective 2023-01-10).
  - Action: entry
  - Agreement: credit facility
  - Counterparty: Innoviva Strategic Opportunities LLC
  - Value: $30 million
  - Effective: 2023-01-10
  source text: On January 10, 2023, Armata Pharmaceuticals, Inc. (the “Company”) entered into, as borrower, a secured convertible credit and security agreement (the “Credit Agreement”) with Innoviva Strategic Opportunities LLC, a wholly owned subsidiary of Innoviva, Inc., a principal shareholder of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/921114/000110465923002496/0001104659-23-002496-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.